Your browser doesn't support javascript.
loading
Systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis.
Cunniffe, Nick; Vuong, Khue Anh; Ainslie, Debbie; Baker, David; Beveridge, Judy; Bickley, Sorrel; Camilleri, Patrick; Craner, Matthew; Fitzgerald, Denise; de la Fuente, Alerie G; Giovannoni, Gavin; Gray, Emma; Hazlehurst, Lorraine; Kapoor, Raj; Kaur, Ranjit; Kozlowski, David; Lumicisi, Brooke; Mahad, Don; Neumann, Björn; Palmer, Alan; Peruzzotti-Jametti, Luca; Pluchino, Stefano; Robertson, Jennifer; Rothaul, Alan; Shellard, Lyndsey; Smith, Kenneth J; Wilkins, Alastair; Williams, Anna; Coles, Alasdair.
Afiliação
  • Cunniffe N; Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK ngc26@cam.ac.uk.
  • Vuong KA; Multiple Sclerosis Society, London, UK.
  • Ainslie D; Research Network, Multiple Sclerosis Society, London, UK.
  • Baker D; Blizard Institute, Queen Mary University of London, London, UK.
  • Beveridge J; Research Network, Multiple Sclerosis Society, London, UK.
  • Bickley S; Multiple Sclerosis Society, London, UK.
  • Camilleri P; Independent consultant, Stevenage, UK.
  • Craner M; Department of Neurology, University of Oxford, Oxford, UK.
  • Fitzgerald D; Wellcome-Wolfson Institute for Experimental Medicine, Queen's Univeristy, Belfast, UK.
  • de la Fuente AG; Wellcome-Wolfson Institute for Experimental Medicine, Queen's Univeristy, Belfast, UK.
  • Giovannoni G; Blizard Institute, Queen Mary University of London, London, UK.
  • Gray E; Multiple Sclerosis Society, London, UK.
  • Hazlehurst L; Research Network, Multiple Sclerosis Society, London, UK.
  • Kapoor R; Faculty of Brain Sciences, Queen Square Institute of Neurology, University College London, London, UK.
  • Kaur R; Research Network, Multiple Sclerosis Society, London, UK.
  • Kozlowski D; Research Network, Multiple Sclerosis Society, London, UK.
  • Lumicisi B; Multiple Sclerosis Society, London, UK.
  • Mahad D; Centre for Clinical Brain Sciences, Anne Rowling Regenerative Neurology Clinic, University of Edinburgh, Edinburgh, UK.
  • Neumann B; Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
  • Palmer A; University of Reading, Reading, Berkshire, UK.
  • Peruzzotti-Jametti L; Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
  • Pluchino S; Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
  • Robertson J; Multiple Sclerosis Society, London, UK.
  • Rothaul A; Independent consultant, Woodstock, Oxfordshire, UK.
  • Shellard L; Research Network, Multiple Sclerosis Society, London, UK.
  • Smith KJ; Department of Neuroinflammation, Queen Square Institute of Neurology, University College London, London, UK.
  • Wilkins A; Department of Neurology, University of Bristol, Bristol, UK.
  • Williams A; MS Centre, Centre for regenerative medicine, University of Edinburgh, Edinburgh, UK.
  • Coles A; Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
J Neurol Neurosurg Psychiatry ; 92(3): 295-302, 2021 03.
Article em En | MEDLINE | ID: mdl-33184094
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Crônica Progressiva / Reposicionamento de Medicamentos Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Crônica Progressiva / Reposicionamento de Medicamentos Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article